AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein Wnt-5a

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P41221

UPID:

WNT5A_HUMAN

Alternative names:

-

Alternative UPACC:

P41221; A8K4A4; Q6P278

Background:

Protein Wnt-5a, encoded by the gene with accession number P41221, plays a pivotal role in various cellular processes. It serves as a ligand for frizzled family receptors, influencing Wnt signaling pathways. Depending on the receptor context, Wnt-5a can either activate or inhibit canonical Wnt signaling, crucial for cell migration, proliferation, and embryogenesis. It is instrumental in limb and genital tubercle outgrowth and chondrogenesis, by modulating beta-catenin levels.

Therapeutic significance:

The involvement of Protein Wnt-5a in Robinow syndrome, autosomal dominant 1, underscores its potential as a therapeutic target. This condition, characterized by dwarfism and facial abnormalities, highlights the protein's significance in developmental processes. Understanding the role of Protein Wnt-5a could open doors to potential therapeutic strategies for managing this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.